Taxol
Executive Summary
Phase II trials in second-line therapy for ovarian carcinoma show an overall 36% remission rate in 41 patients previously treated with cisplatin. Results were reported by Tate Thigpen, MD, University of Missipppi Medical Center at a recent meeting of the American Society of Clinical Oncologists. Of the 15 remissions, five were complete. Eight of the remissions, two complete and six partial, occurred in the 27 patients who were resistant to cisplatin therapy. The major adverse effect was myelosuppression which occurred in 65% of the women on taxol. Availability of the drug is limited since it must be extracted from tree bark.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.